ConvaTec (GB:CTEC) has released an update.
ConvaTec Group PLC reports a strong first half of 2024 with broad-based organic revenue growth of 6.6%, further strategic progress with new product launches, and improved profitability, including an 8.2% increase in adjusted operating profit and a significant boost in free cash flow to equity. The healthcare company also confirms its full-year guidance for 2024, expecting organic revenue growth in the upper half of the 5-7% range, and maintains confidence in achieving its medium-term targets, including margin expansion and double-digit growth in key financial metrics.
For further insights into GB:CTEC stock, check out TipRanks’ Stock Analysis page.
